Acura Pharmaceuticals, Inc. has filed an updated loan schedule with the Securities and Exchange Commission, detailing a total outstanding principal balance of $11,294,279 owed to Abuse Deterrent Pharma, LLC. The filing, dated October 6, 2026, details a series of recent advances made by the lender to the pharmaceutical company.
The schedule indicates that the current principal balance aggregates the original $2,319,279 from a Secured Promissory Note dated November 10, 2022, with 50 additional loans ranging from December 22, 2022, through December 31, 2025. The most recent advances include a $100,000 loan made on September 18, 2026, and a final $100,000 loan made on October 2, 2026.
The promissory note currently bears interest at an annual rate of 5.25%. The company reports accrued interest of approximately $1,365,000 as of September 30, 2026. The agreement includes specific events of default, such as bankruptcy events, failure to pay interest or principal for five days, or the inability to pay debts as they become due. If an event of default occurs, overdue amounts accrue interest at a rate of 7.5% per annum.
In the filing, Acura disclosed that the funding provided by Abuse Deterrent Pharma is being used to meet day-to-day operational activities. The company stated that in the absence of additional financing by mid-October 2026, it would be required to scale back operations, including furloughing and laying off employees, or terminate operations and seek protection under applicable bankruptcy laws.
